Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.86 USD
Change Today -0.09 / -1.01%
Volume 454.7K
SCLN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

sciclone pharmaceuticals inc (SCLN) Snapshot

Open
$8.96
Previous Close
$8.95
Day High
$9.00
Day Low
$8.76
52 Week High
03/12/15 - $9.65
52 Week Low
04/15/14 - $4.24
Market Cap
443.5M
Average Volume 10 Days
347.1K
EPS TTM
$0.62
Shares Outstanding
50.1M
EX-Date
--
P/E TM
14.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for SCICLONE PHARMACEUTICALS INC (SCLN)

sciclone pharmaceuticals inc (SCLN) Related Bloomberg News

View More Bloomberg News

sciclone pharmaceuticals inc (SCLN) Related Businessweek News

No Related Businessweek News Found

sciclone pharmaceuticals inc (SCLN) Details

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People’s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. The company also focuses on development ZADAXIN for the treatment of sepsis. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, Eastern Europe, and the Middle East regions. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. In addition, it markets approximately seven partnered products in China, including Aggrastat, an interventional cardiology product. Further, the company holds license, promotion, distribution, or marketing agreements with various parties for products, including DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, ProFlow, Angiomax, and Cleviprex. SciClone Pharmaceuticals, Inc. also has an agreement with MEDA Pharma GmbH & Co. KG for the development of Tramadol. The company was founded in 1989 and is headquartered in Foster City, California.

570 Employees
Last Reported Date: 03/12/15
Founded in 1989

sciclone pharmaceuticals inc (SCLN) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $550.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $160.4K
Chief Executive Officer of China Operations
Total Annual Compensation: $347.8K
Vice President of Finance and Chief Financial...
Total Annual Compensation: $279.4K
Vice President of Internal Audit
Total Annual Compensation: $273.5K
Compensation as of Fiscal Year 2013.

sciclone pharmaceuticals inc (SCLN) Key Developments

SciClone Pharmaceuticals, Inc. Presents at China Healthcare Investment Conference - Beijing, Mar-23-2015

SciClone Pharmaceuticals, Inc. Presents at China Healthcare Investment Conference - Beijing, Mar-23-2015 . Venue: China World Shangri-La Hotel, Beijing, China. Speakers: Friedhelm Blobel, Chief Executive Officer, President, Executive Director and Member of Business Development Committee.

SciClone Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

SciClone Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $41,425,000 compared to $32,734,000 for the same period in 2013. Income from operations was $3,576,000 compared with $815,000 a year ago. Income before provision for income tax was $3,925,000 compared with $850,000 a year ago. Net income was $3,519,000 or $0.07 per basic and diluted share compared with $36,000 or $0.00 per basic and diluted share a year ago. Non-GAAP net income was $15,375,000 or $0.29 per diluted share compared with $4,016,000 or $0.07 per diluted share a year ago. For the year, the company's total revenues were $134,790,000 compared to $127,058,000 for the same period in 2013. Income from operations was $25,984,000 compared with $10,429,000 a year ago. Income before provision for income tax was $26,377,000 compared with $13,206,000 a year ago. Net income was $25,208,000 or $0.48 per diluted share compared with $10,964,000 or $0.20 per basic and diluted share a year ago. Non-GAAP net income was $39,673,000 or $0.75 per diluted share compared with $23,152,000 or $0.42 per diluted share a year ago. The company projects its 2015 revenue to be in the range between $153 and $158 million, driven by ZADAXIN revenues; and its non-GAAP earnings per share to be in the range between $0.73 and $0.77.

SciClone Seeks Acquisitions

Friedhelm Blobel, Chief Executive Officer of SciClone Pharmaceuticals, Inc. (NasdaqGS:SCLN) said, "For 2015, we anticipate continued growth of ZADAXIN sales, progress in our development pipeline, and continued pursuit of strategic opportunities to augment our portfolio with additional in-licensing and promotional transactions. As the China market continues to evolve, we believe that our sales acumen, the reputation of our sales organization, our market knowledge and our extensive compliance program will continue to be strong partnering assets. Our strong cash flow and cash balance, combined with operating efficiencies and well managed organizational growth, should continue to provide us with the resources to acquire potentially valuable assets that can continue to drive our growth and strengthen our position in the China pharma market."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLN:US $8.86 USD -0.09

SCLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lannett Co Inc $67.71 USD -0.15
Momenta Pharmaceuticals Inc $15.20 USD +0.02
Pernix Therapeutics Holdings Inc $10.69 USD +0.17
Sagent Pharmaceuticals Inc $23.25 USD +0.02
Sarepta Therapeutics Inc $13.28 USD -0.59
View Industry Companies
 

Industry Analysis

SCLN

Industry Average

Valuation SCLN Industry Range
Price/Earnings 18.1x
Price/Sales 3.3x
Price/Book 2.8x
Price/Cash Flow 17.2x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCICLONE PHARMACEUTICALS INC, please visit www.sciclone.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.